{"id":"atazanavir-ritonavir-stavidine-lamivudine","safety":{"commonSideEffects":[{"rate":"~40-50","effect":"Hyperbilirubinemia (unconjugated)"},{"rate":"~15-20","effect":"Nausea"},{"rate":"~10-15","effect":"Diarrhea"},{"rate":"~10-15","effect":"Headache"},{"rate":"~15-20","effect":"Peripheral neuropathy (stavudine-related)"},{"rate":"~20-30","effect":"Lipodystrophy (stavudine-related)"},{"rate":"<1","effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that prevents HIV protease from cleaving viral polyproteins, while ritonavir boosts atazanavir levels by inhibiting its metabolism. Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors that block the enzyme responsible for converting HIV RNA into DNA, preventing viral integration into host cells.","oneSentence":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:19.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00084253","phase":"PHASE4","title":"Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"HIV Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reyataz"],"phase":"marketed","status":"active","brandName":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","genericName":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}